Definium Therapeutics, Inc. (DFTX)
| Market Cap | 4.53B +268.6% |
| Revenue (ttm) | n/a |
| Net Income | -337.48M |
| EPS | -2.96 |
| Shares Out | 136.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,412 |
| Open | 33.10 |
| Previous Close | 33.00 |
| Day's Range | 32.79 - 33.35 |
| 52-Week Range | 10.47 - 49.70 |
| Beta | 2.21 |
| Analysts | Strong Buy |
| Price Target | 72.78 (+119.88%) |
| Earnings Date | Nov 9, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $72.78, which is an increase of 119.88% from the latest price.
News
Psychedelic: Definium Therapeutics narrows quarterly net loss
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a NDA submission and a psilocybin shipment. EARNINGS: On Monday, Definium…
Definium Therapeutics reports Q3 EPS (46c), consensus (56c)
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demons...
Definium Therapeutics price target raised to $70 from $66 at RBC Capital
RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $66 and keeps an Outperform rating on the shares after its Q3 results. Regulatory updates are…
Definium Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
DT120’s three positive Phase III readouts support a planned H1 2027 NDA, with efforts to pursue GAD and MDD labels. A five-person DT402 cohort showed a consistent exposure-linked signal, prompting continued ASD development.
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Definium Therapeutics Earnings Call Transcript: Q3 2026
Three positive Phase III DT120 studies and FDA designations support an H1 2027 NDA plan, while ~$1.05B in cash and investments is expected to fund operations into 2030. DT402 findings also support further ASD development.
Definium Therapeutics Earnings release: Q3 2026
Definium Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Definium Therapeutics Quarterly report: Q3 2026
Definium Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics ...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics presents Phase 3 data for DT120 ODT at NEI Fall Congress
Definium Therapeutics (DFTX) announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO.T opline results from Panorama, the Company’s s...
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of th...
Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $84 price target The company’s lead asset DT120 ODT is being developed as a treatment for various neuropsychia...
Definium Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Phase III trials of DT120 in GAD and MDD showed robust efficacy and benign safety, with single treatments yielding significant improvements and high response/remission rates. Open-label retreatment in Part B led to 60–70% mild/remission rates, and regulatory discussions are ongoing for potential dual indication filing.
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Definium Therapeutics price target raised to $78 from $64 at Canaccord
Canaccord raised the firm’s price target on Definium Therapeutics (DFTX) to $78 from $64 and keeps a Buy rating on the shares. The firm updated its model following its stellar…
Definium Therapeutics price target raised to $79 from $75 at Baird
Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $79 from $75 and keeps an Outperform rating on the shares. The fim updated its model following solid Panorama…
Definium Therapeutics price target raised to $75 from $70 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $75 from $70 and keeps an Outperform rating on the shares. The firm sees the “positive” Phase 3 Panorama…
Definium Therapeutics price target raised to $91 from $75 at BofA
BofA raised the firm’s price target on Definium Therapeutics (DFTX) to $91 from $75 and keeps a Buy rating on the shares. Definium reported positive topline results from the Phase…
First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.
Definium Therapeutics Transcript: Study result
Panorama phase III results show DT120 100 mcg delivers rapid, robust, and durable efficacy in GAD, with a strong safety profile and consistent benefit across subgroups. Long-term data support sustained response and benefit from intermittent retreatment. NDA filing is planned for 2027.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Definium Therapeutics Slides: Study result
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.